[1]黄 斌,谭洁芬,刘燕萍,等.达格列净联合利格列汀在肥胖2型糖尿病患者中的效果及安全性[J].医学信息,2024,37(17):124-126130.[doi:10.3969/j.issn.1006-1959.2024.17.026]
　HUANG Bin,TAN Jie-fen,LIU Yan-ping,et al.Effect and Safety of Dapagliflozin Combined with Linagliptin in Obese Patientswith Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(17):124-126130.[doi:10.3969/j.issn.1006-1959.2024.17.026]
点击复制

达格列净联合利格列汀在肥胖2型糖尿病患者中的效果及安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年17期
页码:
124-126130
栏目:
论著
出版日期:
2024-09-01

文章信息/Info

Title:
Effect and Safety of Dapagliflozin Combined with Linagliptin in Obese Patientswith Type 2 Diabetes Mellitus
文章编号:
1006-1959（2024）17-0124-04
作者:
黄 斌; 谭洁芬; 刘燕萍; 谭金权; 陈 斌
全南县人民医院，江西 全南 341800
Author(s):
HUANG Bin; TAN Jie-fen; LIU Yan-ping; TAN Jin-quan; CHEN Bin
Quannan County People’s Hospital,Quannan 341800,Jiangxi,China
关键词:
达格列净; 利格列汀; 肥胖2型糖尿病; 胰岛素抵抗指数
Keywords:
Dapagliflozin; Ligliptin; Obesity type 2 diabetes mellitus; Insulin resistance index
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2024.17.026
文献标志码:
A
摘要:
目的 分析达格列净联合利格列汀治疗肥胖2型糖尿病患者的效果。方法 选取2021年6月-2023年6月我院收治的80例肥胖2型糖尿病患者为研究对象，按照随机数字表法将其分为对照组（n=40）和研究组（n=40）。对照组给予利格列汀治疗，研究组在对照组基础上联合利格列汀治疗，比较两组血糖指标[空腹血糖（FPG）、糖化血红蛋白（HbA1c）、胰岛素抵抗指数、血脂指标[总胆固醇（TC）、三酰甘油（TG）]、肾功能指标[尿微量白蛋白（UAlb）、尿白蛋白/肌酐比值（UACR），血清肌酐浓度（SCr）]、不良反应发生率。结果 两组治疗后胰岛素抵抗指数均低于治疗前，且研究组低于对照组（P＜0.05）；两组治疗后FPG、HbA1c均低于治疗前，且研究组低于对照组（P＜0.05）；两组治疗前后TC、TG水平比较，差异无统计学意义（P＞0.05）；两组治疗后UAlb、UACR、SCr均低于治疗前，且研究组低于对照组（P＜0.05）；研究组不良反应发生率与对照组比较，差异无统计意义（P＞0.05）。结论 达格列净联合利格列汀在肥胖2型糖尿病患者中的效果确切，可有效控制血糖指标，改善肾功能，降低胰岛素抵抗，且不会增加不良反应，是一种有效、可靠的治疗方案。
Abstract:
Objective To analyze the effect of dapagliflozin combined with linagliptin in the treatment of obese patients with type 2 diabetes mellitus.Methods A total of 80 obese patients with type 2 diabetes mellitus admitted to our hospital from June 2021 to June 2023 were selected as the research objects. They were divided into control group (n=40) and study group (n=40) according to the random number table method. The control group was treated with linagliptin, and the study group was treated with linagliptin on the basis of the control group. The blood glucose indexes [fasting blood glucose (FPG), glycosylated hemoglobin (HbA1c), insulin resistance index, blood lipid indexes [total cholesterol (TC), triglyceride (TG)], renal function indexes [urinary microalbumin (UAlb), urinary albumin/creatinine ratio (UACR), serum creatinine concentration (SCr)] and incidence of adverse reactions were compared between the two groups.Results The insulin resistance index of the two groups after treatment was lower than that before treatment, and that of the study group was lower than that of the control group (P<0.05). After treatment, FPG and HbA1 c in the two groups were lower than those before treatment, and those in the study group were lower than the control group (P<0.05). There was no significant difference in TC and TG levels between the two groups before and after treatment (P>0.05). After treatment, UAlb, UACR and SCr in the two groups were lower than those before treatment, and those in the study group were lower than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the study group and the control group (P>0.05).Conclusion Dapagliflozin combined with linagliptin is effective in obese patients with type 2 diabetes mellitus, which can effectively control blood glucose index, improve renal function, reduce insulin resistance, and will not increase adverse reactions. It is an effective and reliable treatment plan.

参考文献/References:

[1]陈晓军,曾建.达格列净对利拉鲁肽治疗后超重/肥胖2型糖尿病患者的疗效[J].武警医学,2020,31(7):557-560.[2]梁琦琦,齐昊,韩笑.达格列净联合胰岛素对2型糖尿病病人血糖波动的影响[J].中西医结合心脑血管病杂志,2020,18(12):1957-1960.[3]周换丽,孔艳华.阿格列汀或达格列净联合二甲双胍治疗2型糖尿病的疗效[J].临床与病理杂志,2020,40(5):1169-1173.[4]陈诚,邓斌.恩格列净联合利格列汀治疗2型糖尿病的临床研究[J].药物评价研究,2020,43(5):880-884.[5]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.[6]Kanazawa A,Aida M,Yoshida Y,et al.Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study[J].Nutrients,2021,13(2):558.[7]王卓彪,刘永兰.二甲双胍联合阿卡波糖对2型糖尿病的临床治疗效果[J].中国药物与临床,2019,19(15):2612-2613.[8]《缓解型糖尿病中国专家共识》编写专家委员会.缓解2型糖尿病中国专家共识[J].中国全科医学,2021,24(32):4037-4048.[9]吴立,罗翔.瑞格列奈联合利格列汀治疗糖尿病肾病40例观察[J].吉林医学,2020,41(4):839-840.[10]魏伟,栗夏莲.达格列净联合维格列汀治疗2型糖尿病肾病[J].河南医学研究,2020,29(2):286-288.[11]韩娥.达格列净对2型糖尿病胰岛素泵短期强化治疗患者胰岛素抵抗指数影响研究[J].临床军医杂志,2020,48(4):437-438.[12]任虎君,张佳佳,程杨阳,等.达格列净治疗2型糖尿病肾病患者的临床观察[J].华南国防医学杂志,2019,33(12):838-841.[13]金雯瑜.格列齐特联合利格列汀治疗2型糖尿病的临床研究[J].山西医药杂志,2019,48(17):2143-2145.[14]牟伦盼,蒋建家,张雅萍,等.达格列净与利格列汀对口服降糖药控制不佳的超重或肥胖2型糖尿病患者的疗效和安全性比较[J].中华糖尿病杂志,2019,11(3):190-195.[15]和明丽,丁奇龙,王俊军.利格列汀联合二甲双胍治疗超重和肥胖2型糖尿病患者的疗效及对血清脂肪因子变化的影响[J].中国医师杂志,2020,22(4):589-592.[16]李明,门敏,李楠,等.α-硫辛酸联合达格列净对2型糖尿病患者糖脂代谢和氧化应激的影响[J].疑难病杂志,2019,18(9):872-876.[17]那彩霞,何一飞,赵静.利格列汀对2型糖尿病合并肥胖患者糖脂代谢指标及胰岛β细胞分泌功能的影响[J].中国临床实用医学,2020,11(2):37-40.[18]管雅文,金水平,陈建华,等.利格列汀对2型糖尿病合并帕金森病患者运动功能影响的临床研究[J].海军医学杂志,2020,41(3):295-298,302.[19]莫小庆,黄春,赵燕妮,等.达格列净对2型糖尿病合并冠心病患者血清hs-CRP、脂联素及胰岛素水平的影响观察[J].中国医药科学,2019,9(14):193-196.[20]范晓霞,姚勇利,胡耀嘉,等.超重和肥胖2型糖尿病伴微量白蛋白尿患者使用达格列净或沙格列汀控制血糖疗效和安全性的观察[J].中国糖尿病杂志,2020,28(2):85-88.

相似文献/References:

[1]孙寿广.达格列净治疗2型糖尿病的研究进展[J].医学信息,2018,31(19):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
　SUN Shou-guang.Progress in the Study of Dapagliflozin in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2018,31(17):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
[2]董 健.达格列净治疗2型糖尿病的疗效及其对体质指数的影响[J].医学信息,2020,33(07):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
　DONG Jian.The Therapeutic Effect of Dapagliflozin on Type 2 Diabetes and Its Influence on Body Mass Index[J].Journal of Medical Information,2020,33(17):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
[3]樊小莉.达格列净治疗老年糖尿病的临床疗效及其对肾功能影响[J].医学信息,2020,33(13):158.[doi:10.3969/j.issn.1006-1959.2020.13.048]
　FAN Xiao-li.The Clinical Efficacy of Dapagliflozin in the Treatment of Senile Diabetes and Its Influence on Renal Function[J].Journal of Medical Information,2020,33(17):158.[doi:10.3969/j.issn.1006-1959.2020.13.048]
[4]郑黄生,周炳凤.钠-葡萄糖协同转运蛋白-2抑制剂治疗射血分数降低心力衰竭的疗效及预后分析[J].医学信息,2021,34(10):92.[doi:10.3969/j.issn.1006-1959.2021.10.025]
　ZHENG Huang-sheng,ZHOU Bing-feng.Efficacy and Prognosis of Sodium-glucose Cotransporter-2 Inhibitor in Treatment of Heart Failure with Lower Ejection Fraction[J].Journal of Medical Information,2021,34(17):92.[doi:10.3969/j.issn.1006-1959.2021.10.025]
[5]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(17):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[6]廖 萌,淦作梅.达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响[J].医学信息,2024,37(13):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
　Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type Diabetes Mellitus.Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(17):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
[7]杨秀萍.格列净联合常规抗心衰药物治疗射血分数下降心衰患者的疗效[J].医学信息,2024,37(20):84.[doi:10.3969/j.issn.1006-1959.2024.20.015]
　YANG Xiuping.Efficacy of Dapagliflozin Combined with Conventional Anti-heart Failure Drugs in the Treatment of Heart Failure Patients with Reduced Ejection Fraction[J].Journal of Medical Information,2024,37(17):84.[doi:10.3969/j.issn.1006-1959.2024.20.015]
[8]刘 璇,陈珍珍.达格列净联合二甲双胍在2型糖尿病治疗中的临床疗效[J].医学信息,2025,38(02):116.[doi:10.3969/j.issn.1006-1959.2025.02.021]
　LIU Xuan,CHEN Zhenzhen.Clinical Efficacy of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2025,38(17):116.[doi:10.3969/j.issn.1006-1959.2025.02.021]

更新日期/Last Update: 1900-01-01